- Home
- AUTL
as of 02-06-2026 3:44pm EST
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 433.8M | IPO Year: | 2018 |
| Target Price: | $8.33 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.10 - $2.70 | Next Earning Date: | 03-19-2026 |
| Revenue: | $51,128,000 | Revenue Growth: | 406.67% |
| Revenue Growth (this year): | 672.42% | Revenue Growth (next year): | 84.48% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -285219000.0 | FCF Growth: | N/A |
AI-Powered AUTL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare AUTL vs Leading Stocks
See how AUTL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AUTL Autolus Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.